Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Novel KarX and KarT Prototypes in Healthy Adults
NCT07063342Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xanomeline and trospium in schizophrenia (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration, Time of maximum observed concentration and 11 more. Started Jun 2025; status: recruiting.
02
Drugs
xanomelinetrospium
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07063342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063342.